Health-related quality of life in patients with high-risk melanoma randomised in the Nordic phase 3 trial with adjuvant intermediate-dose interferon alfa-2b - Brandberg, Y.; Aamdal, S.; Bastholt, L.; Hernberg, M.; Stierner, U.; von der Maase, H.; Hansson, J. (European Journal of Cancer, 2012)